Literature DB >> 29869584

Hepatitis C antibody reactivity among high-risk rural women: opportunities for services and treatment in the criminal justice system.

Justin C Strickland1, Michele Staton2,3, Carl G Leukefeld2,3, Carrie B Oser3,4, J Matthew Webster2,3.   

Abstract

Purpose The purpose of this paper is to examine the drug use and criminal justice factors related to hepatitis C virus (HCV) antibody reactivity among rural women in the USA recruited from local jails. Design/methodology/approach Analyses included 277 women with a history of injection drug use from three rural jails in Kentucky. Participants completed health and drug use questionnaires and received antibody testing for HCV. Findings The majority of women tested reactive to the HCV antibody (69 percent). Reactivity was associated with risk factors, such as unsterile needle use. Criminal justice variables, including an increased likelihood of prison incarceration, an earlier age of first arrest, and a longer incarceration history, were associated with HCV reactive tests. Participants also endorsed several barriers to seeking healthcare before entering jail that were more prevalent in women testing HCV reactive regardless of HCV status awareness before entering jail. Originality/value Injection and high-risk sharing practices as well as criminal justice factors were significantly associated with HCV reactivity. Future research and practice could focus on opportunities for linkages to HCV treatment during incarceration as well as during community re-entry to help overcome real or perceived treatment barriers. The current study highlights the importance of the criminal justice system as a non-traditional, real-world setting to examine drug use and related health consequences such as HCV by describing the association of high-risk drug use and criminal justice consequences with HCV among rural women recruited from local jails.

Entities:  

Keywords:  Barriers; Cocaine; Injection drug use; Jail; Offender health; Substance use

Mesh:

Substances:

Year:  2018        PMID: 29869584      PMCID: PMC6121220          DOI: 10.1108/IJPH-03-2017-0012

Source DB:  PubMed          Journal:  Int J Prison Health        ISSN: 1744-9200


  36 in total

1.  A survey of HIV and HCV among female prison inmates in Portugal.

Authors:  Henrique Barros; Elisabete Ramos; Raquel Lucas
Journal:  Cent Eur J Public Health       Date:  2008-09       Impact factor: 1.163

2.  Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross-sectional comparison and retrospective survival analysis.

Authors:  April M Young; Jennifer R Havens
Journal:  Addiction       Date:  2011-10-26       Impact factor: 6.526

3.  A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections.

Authors:  Curt G Beckwith; Ann E Kurth; Lauri B Bazerman; Emily J Patry; Alice Cates; Liem Tran; Amanda Noska; Irene Kuo
Journal:  J Public Health (Oxf)       Date:  2015-03-02       Impact factor: 2.341

4.  Hepatitis C virus infection among prisoners in the California state correctional system.

Authors:  Rena K Fox; Sue L Currie; Jennifer Evans; Teresa L Wright; Leslie Tobler; Bruce Phelps; Michael P Busch; Kimberly A Page-Shafer
Journal:  Clin Infect Dis       Date:  2005-06-09       Impact factor: 9.079

5.  Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users.

Authors:  Jennifer R Havens; Michelle R Lofwall; Simon D W Frost; Carrie B Oser; Carl G Leukefeld; Richard A Crosby
Journal:  Am J Public Health       Date:  2012-11-15       Impact factor: 9.308

6.  Limited uptake of hepatitis C treatment among injection drug users.

Authors:  Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas
Journal:  J Community Health       Date:  2008-06

7.  The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.

Authors:  M J Alter; H S Margolis; K Krawczynski; F N Judson; A Mares; W J Alexander; P Y Hu; J K Miller; M A Gerber; R E Sampliner
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

8.  Risk factors for HCV infection among young adults in rural New York who inject prescription opioid analgesics.

Authors:  Jon E Zibbell; Rachel Hart-Malloy; John Barry; Lillian Fan; Colleen Flanigan
Journal:  Am J Public Health       Date:  2014-09-11       Impact factor: 9.308

Review 9.  Hepatitis C virus therapy update 2013.

Authors:  Lisa C Casey; William M Lee
Journal:  Curr Opin Gastroenterol       Date:  2013-05       Impact factor: 3.287

10.  Testing for HCV infection: an update of guidance for clinicians and laboratorians.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-05-10       Impact factor: 17.586

View more
  2 in total

1.  Kentucky Women's Justice Community Opioid Innovation Network (JCOIN): A type 1 effectiveness-implementation hybrid trial to increase utilization of medications for opioid use disorder among justice-involved women.

Authors:  Michele Staton; J Matthew Webster; Carl Leukefeld; Martha Tillson; Katherine Marks; Carrie Oser; Heather M Bush; Laura Fanucchi; Amanda Fallin-Bennett; Bryan R Garner; Kathryn McCollister; Sarah Johnson; Erin Winston
Journal:  J Subst Abuse Treat       Date:  2021-01-09

2.  Eliminating hepatitis C in a rural Appalachian county: protocol for the Kentucky Viral Hepatitis Treatment Study (KeY Treat), a phase IV, single-arm, open-label trial of sofosbuvir/velpatasvir for the treatment of hepatitis C.

Authors:  Jennifer R Havens; Takako Schaninger; Hannah Fraser; Michelle Lofwall; Michele Staton; April M Young; Ardis Hoven; Sharon L Walsh; Peter Vickerman
Journal:  BMJ Open       Date:  2021-07-05       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.